ADVA
17.12.2020 09:02:17 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that StarHub is harnessing its FSP 3000 ConnectGuard ™ Optical Layer 1 encryption technology to power the StarHub SDS Secured Service. This fully-managed service enables local enterprises, government agencies and multinational corporations to harness telco-grade encrypted connectivity for their users and systems across multiple locations, with ultra-fast performance and competitive pricing. With StarHub SDS Secured Service, enterprise customers managing highly-confidential and mission-critical information can be assured that all data transfers between their offices, disaster recovery sites and data centers are fully encrypted down to the fiber network level, which is operated and fully owned by StarHub.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005032/en/
“In today’s fast-evolving security climate, we are delighted to be partners with ADVA to meet our corporate and government clients’ need for the most comprehensive and effective data security solutions. Operating an extensive private fiber infrastructure, we are in a prime position to help customers quickly and cost-effectively encrypt every bit of data right at the base network level, augmenting their existing firewalls and endpoint protection services to safeguard their mission-critical network connections against unauthorized access,” said Sander Veraar, VP, product management, Enterprise Business Group, StarHub. “With StarHub SDS Secured Service, our customers will enjoy not only robust security features, but also maximum network uptime with automatic traffic re-routing and redundancy as well as 24x7 support.”
The StarHub SDS Secured Service delivers highly-reliable and robustly protected enterprise connectivity on protocols including Ethernet, Fibre Channel and Synchronous Digital Hierarchy (SDH), and with a choice of speeds ranging from 1Gbit/s to 100Gbit/s. Physical layer encryption throughout the network ensures all customer data has the most rigorous defense available. Key security features for customers include protocol-agnostic hardware-based encryption with the lowest latency possible and 100% throughput. Security is also enhanced through simple certificate enrolment protocol-based automation and manual operations, as well as a strictly separated encryption domain manager. What’s more, the solution features automated procedures for authentication, services creation and regular key generation. As the only technology of its kind cleared to transport NATO-restricted data, the ADVA FSP 3000 ConnectGuard™ Optical encryption solution meets the most stringent international standards and regulatory requirements.
“We’re excited to be StarHub’s technology partner as it takes this key step. The StarHub SDS Secured Service offers a major boost to the business community in Singapore, providing the protection as well as the speed and guaranteed uptime needed for the most sensitive and critical data transport,” commented Erik Lindberg, VP, sales, APAC, ADVA. “Our ConnectGuard™ Optical encryption solution is the ideal technology for protecting customer data and trust. Because it encrypts at the transport layer, it does not impact performance. That guarantee of data integrity with regards to latency and throughput is crucial. It’s a major advantage for networks that depend on low latency, such as those interconnecting data centers of financial and government institutions.”
Further information on the StarHub SDS Secured Service is available here: https://adva.li/starhub-sds-secured-service .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About StarHub
StarHub is a leading homegrown Singapore company that delivers world-class communications, entertainment and digital solutions. With our extensive fibre and wireless infrastructure and global partnerships, we bring to people, homes and enterprises quality mobile and fixed services, a broad suite of premium content, and a diverse range of communication solutions. We develop and deliver to corporate and government clients solutions incorporating artificial intelligence, cyber security, data analytics, Internet of Things and robotics. We are committed to conducting our business in a sustainable and environmentally responsible manner. Launched in 2000 and listed on the Singapore Exchange mainboard since 2004, StarHub is a component stock of the SGX Sustainability Leaders Index and the SGX Sustainability Leaders Enhanced Index. Find us at www.starhub.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005032/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom